JP2020517719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517719A5 JP2020517719A5 JP2019558554A JP2019558554A JP2020517719A5 JP 2020517719 A5 JP2020517719 A5 JP 2020517719A5 JP 2019558554 A JP2019558554 A JP 2019558554A JP 2019558554 A JP2019558554 A JP 2019558554A JP 2020517719 A5 JP2020517719 A5 JP 2020517719A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- muscarinic receptor
- receptor antagonist
- nri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 13
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 13
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 10
- -1 ediboxetine Chemical compound 0.000 claims 9
- 239000003149 muscarinic antagonist Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 7
- 229960002430 atomoxetine Drugs 0.000 claims 7
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 7
- 229960005434 oxybutynin Drugs 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 5
- 206010041235 Snoring Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 229960003770 reboxetine Drugs 0.000 claims 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 2
- 229960002646 scopolamine Drugs 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims 1
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 claims 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 1
- GFRUPHOKLBPHTQ-UHFFFAOYSA-N 2-(2-cyclohexyl-2-hydroxy-1-oxo-2-phenylethoxy)ethyl-diethyl-methylammonium Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCCC1 GFRUPHOKLBPHTQ-UHFFFAOYSA-N 0.000 claims 1
- GKNPSSNBBWDAGH-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 GKNPSSNBBWDAGH-UHFFFAOYSA-N 0.000 claims 1
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 claims 1
- 229930003347 Atropine Natural products 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- ZRYHPQCHHOKSMD-UHFFFAOYSA-N Hexocyclium Chemical compound C1C[N+](C)(C)CCN1CC(O)(C=1C=CC=CC=1)C1CCCCC1 ZRYHPQCHHOKSMD-UHFFFAOYSA-N 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- JTPUMZTWMWIVPA-UHFFFAOYSA-O Isopropamide Chemical compound C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 JTPUMZTWMWIVPA-UHFFFAOYSA-O 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims 1
- HBGWAZBZXJBYQD-UHFFFAOYSA-N amedalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)C(=O)N1C1=CC=CC=C1 HBGWAZBZXJBYQD-UHFFFAOYSA-N 0.000 claims 1
- 229950000203 amedalin Drugs 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 229940118324 anisotropine Drugs 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- 229960000910 bethanechol Drugs 0.000 claims 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 claims 1
- 229960003003 biperiden Drugs 0.000 claims 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- XGGHHHBGPSNXFE-ZSHCYNCHSA-N chembl1186610 Chemical compound C1[C@H](OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C XGGHHHBGPSNXFE-ZSHCYNCHSA-N 0.000 claims 1
- 229960003154 clidinium Drugs 0.000 claims 1
- HOOSGZJRQIVJSZ-NNBUQUNQSA-N clidinium Chemical compound C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HOOSGZJRQIVJSZ-NNBUQUNQSA-N 0.000 claims 1
- HLOCJJORRHQDKS-UHFFFAOYSA-N cp-39,332 Chemical compound C12=CC=CC=C2CC(NC)CC1C1=CC=CC=C1 HLOCJJORRHQDKS-UHFFFAOYSA-N 0.000 claims 1
- YFAIJBZEDDOCAN-UHFFFAOYSA-N daledalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)CN1C1=CC=CC=C1 YFAIJBZEDDOCAN-UHFFFAOYSA-N 0.000 claims 1
- 229950009245 daledalin Drugs 0.000 claims 1
- 229960002677 darifenacin Drugs 0.000 claims 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 1
- 229960001623 desvenlafaxine Drugs 0.000 claims 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 claims 1
- 229960002777 dicycloverine Drugs 0.000 claims 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004890 diethylpropion Drugs 0.000 claims 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 claims 1
- 229960003520 diphenidol Drugs 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 229950008247 esreboxetine Drugs 0.000 claims 1
- 229960002978 fesoterodine Drugs 0.000 claims 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims 1
- 229940015042 glycopyrrolate Drugs 0.000 claims 1
- 229960001666 hexocyclium Drugs 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229960001737 isopropamide Drugs 0.000 claims 1
- 229950004863 lortalamine Drugs 0.000 claims 1
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 claims 1
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 claims 1
- 229950006048 manifaxine Drugs 0.000 claims 1
- 229960003092 mepenzolate Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960005103 metixene Drugs 0.000 claims 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims 1
- 229950004211 nisoxetine Drugs 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 229940083311 nucynta Drugs 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 229960002740 oxyphenonium Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229960005253 procyclidine Drugs 0.000 claims 1
- 229960002601 protriptyline Drugs 0.000 claims 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims 1
- 229950010561 radafaxine Drugs 0.000 claims 1
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 229960003855 solifenacin Drugs 0.000 claims 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 1
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 claims 1
- 229950006964 tandamine Drugs 0.000 claims 1
- 229960005126 tapentadol Drugs 0.000 claims 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 1
- 229960004045 tolterodine Drugs 0.000 claims 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims 1
- 229960001032 trihexyphenidyl Drugs 0.000 claims 1
- 229960001491 trospium Drugs 0.000 claims 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001255 viloxazine Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023108387A JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2025128090A JP2025169279A (ja) | 2017-04-28 | 2025-07-31 | 睡眠時無呼吸を治療する方法及び組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491504P | 2017-04-28 | 2017-04-28 | |
| US62/491,504 | 2017-04-28 | ||
| US201762558814P | 2017-09-14 | 2017-09-14 | |
| US62/558,814 | 2017-09-14 | ||
| PCT/US2018/029518 WO2018200775A1 (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108387A Division JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517719A JP2020517719A (ja) | 2020-06-18 |
| JP2020517719A5 true JP2020517719A5 (https=) | 2021-06-10 |
| JP7373997B2 JP7373997B2 (ja) | 2023-11-06 |
Family
ID=63918622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558554A Active JP7373997B2 (ja) | 2017-04-28 | 2018-04-26 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2023108387A Pending JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2025128090A Pending JP2025169279A (ja) | 2017-04-28 | 2025-07-31 | 睡眠時無呼吸を治療する方法及び組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108387A Pending JP2023139000A (ja) | 2017-04-28 | 2023-06-30 | 睡眠時無呼吸を治療する方法及び組成物 |
| JP2025128090A Pending JP2025169279A (ja) | 2017-04-28 | 2025-07-31 | 睡眠時無呼吸を治療する方法及び組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US11123313B2 (https=) |
| EP (1) | EP3615016A4 (https=) |
| JP (3) | JP7373997B2 (https=) |
| KR (3) | KR20240042261A (https=) |
| CN (2) | CN119185558A (https=) |
| AU (3) | AU2018260666B2 (https=) |
| BR (1) | BR112019022483A2 (https=) |
| CA (1) | CA3061468A1 (https=) |
| CO (1) | CO2019013180A2 (https=) |
| CR (1) | CR20190546A (https=) |
| DO (1) | DOP2019000274A (https=) |
| EC (1) | ECSP19084058A (https=) |
| GE (6) | GEAP202416602A (https=) |
| MA (1) | MA49069A (https=) |
| MX (2) | MX394941B (https=) |
| MY (1) | MY200172A (https=) |
| NI (1) | NI201900110A (https=) |
| PH (1) | PH12019502427A1 (https=) |
| SG (2) | SG10202111623TA (https=) |
| UA (1) | UA127759C2 (https=) |
| WO (1) | WO2018200775A1 (https=) |
| ZA (1) | ZA201907158B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP202416602A (en) * | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| KR102874891B1 (ko) * | 2018-01-30 | 2025-10-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
| CN108309261B (zh) * | 2018-02-11 | 2020-05-22 | 西安交通大学 | 一种猝死预警方法及装置和系统 |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
| CN118557736A (zh) * | 2019-02-08 | 2024-08-30 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| JP7776442B2 (ja) | 2020-05-05 | 2025-11-26 | アプニメッド，インコーポレイテッド（デラウェア） | （ｒ）－オキシブチニン塩酸塩の多形形態 |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| RU2757470C1 (ru) * | 2020-11-19 | 2021-10-18 | Ренат Рашитович Ахмеров | Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы |
| US20240075035A1 (en) * | 2021-01-14 | 2024-03-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| AU2022231133A1 (en) * | 2021-03-04 | 2023-09-21 | Apnimed, Inc. (Delaware) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| US20240189328A1 (en) * | 2021-04-16 | 2024-06-13 | Apnimed, Inc. (Delaware) | Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea |
| US20240277719A1 (en) * | 2021-06-17 | 2024-08-22 | Apnimed, Inc. (Delaware) | Norepinephrine reuptake inhibitors for treating sleep apnea |
| EP4395721A1 (en) * | 2021-08-31 | 2024-07-10 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| KR20240124995A (ko) | 2021-12-22 | 2024-08-19 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물 |
| JP2024545289A (ja) * | 2021-12-22 | 2024-12-05 | バイエル・アクチエンゲゼルシヤフト | 睡眠時無呼吸の治療のためのｔａｓｋ１／３チャネル遮断薬とノルエピネフリン再取込み阻害薬との組合せ |
| CA3259602A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| EP4522149A1 (en) * | 2022-05-13 | 2025-03-19 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU767877B2 (en) | 1999-05-20 | 2003-11-27 | Sepracor, Inc. | Methods for treatment of asthma using S-oxybutynin |
| PT1257277E (pt) * | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| JP2014503593A (ja) * | 2011-01-28 | 2014-02-13 | ファンタスティック・メディカル・リサーチ・インスティテュート・エルエルシー | 閉塞性睡眠時無呼吸を処置するための方法 |
| GEAP202416602A (en) * | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| KR102874891B1 (ko) | 2018-01-30 | 2025-10-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
-
2018
- 2018-04-26 GE GEAP202416602A patent/GEAP202416602A/en unknown
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/en active Pending
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 BR BR112019022483-1A patent/BR112019022483A2/pt active IP Right Grant
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/ja active Active
- 2018-04-26 GE GEAP202115226A patent/GEAP202115226A/en unknown
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/ko not_active Ceased
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 MX MX2019012729A patent/MX394941B/es unknown
- 2018-04-26 CN CN202411366994.9A patent/CN119185558A/zh active Pending
- 2018-04-26 UA UAA201910615A patent/UA127759C2/uk unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 GE GEAP201816320A patent/GEP20257788B/en unknown
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/en not_active Ceased
- 2018-04-26 KR KR1020257032249A patent/KR20250145704A/ko active Pending
- 2018-04-26 CA CA3061468A patent/CA3061468A1/en active Pending
- 2018-04-26 GE GEAP202316320A patent/GEAP202316320A/en unknown
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/zh active Pending
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 CR CR20190546A patent/CR20190546A/es unknown
- 2018-04-26 MA MA049069A patent/MA49069A/fr unknown
- 2018-04-26 KR KR1020197034523A patent/KR102682159B1/ko active Active
-
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/es unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/es unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/es unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/es unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/es unknown
-
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
-
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/ja active Pending
- 2023-07-19 US US18/355,178 patent/US20240189261A1/en not_active Abandoned
-
2024
- 2024-03-04 US US18/594,885 patent/US20240261239A1/en not_active Abandoned
-
2025
- 2025-07-10 US US19/265,336 patent/US20260007618A1/en active Pending
- 2025-07-31 JP JP2025128090A patent/JP2025169279A/ja active Pending
- 2025-09-11 AU AU2025230729A patent/AU2025230729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517719A5 (https=) | ||
| JP2023139000A5 (https=) | ||
| JP6824314B2 (ja) | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 | |
| US8501816B2 (en) | Antitussive compositions comprising memantine | |
| KR20250145704A (ko) | 수면 무호흡을 치료하기 위한 방법 및 조성물 | |
| JP2009525343A5 (https=) | ||
| EP2422778A1 (en) | Titration of tapentadol | |
| JP2021120379A5 (https=) | ||
| RU2007140348A (ru) | Способы и композиции для лечения заболеваний цнс | |
| JP2011509295A5 (https=) | ||
| CN102724878A (zh) | 在重度抑郁症患者中提供体重减轻疗法的方法 | |
| JP6232135B2 (ja) | 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン | |
| CN102805746B (zh) | 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用 | |
| Bied et al. | A critical appraisal of the selegiline transdermal system for major depressive disorder | |
| JP2022506113A5 (https=) | ||
| US9849125B1 (en) | Anti-overingestion dosage forms | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| JP2024511091A5 (https=) | ||
| US11207330B2 (en) | Mirtazapine for use in medication overuse headache based on tension-type headache | |
| JP2024523876A5 (https=) | ||
| Verma et al. | Antihypertensive efficacy of carvedilol and amlodipine in patients of mild to moderate hypertension–a comparative study | |
| GB2510444A (en) | Enhanced combination of phenylephrine and paracetamol | |
| JP2025500344A5 (https=) | ||
| JP2024508498A5 (https=) | ||
| EP2453885A1 (en) | Exo-s-mecamylamine method, use, and compound for treatment |